ReviewJournal of clinical and translational hepatology2018
Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review.
Review in Journal of clinical and translational hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 3 syntheses or guidelines pooled it, 254 citations in OpenAlex.
- Synchronous Telemedicine Versus In-Person Care in Hepatitis C Treatment: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Pooled it
- PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC.Epigenetics · 2026Article
- Transcriptomic and Zonal Signatures of Mitochondrial Peroxisomal Dysfunction in HCV Associates with Circulating Mitochondrial DNA Biomarkers.Current issues in molecular biology · 2026Article
- Comprehensive Evaluation of the Elecsys HCV Duo Immunoassay for Active Hepatitis C Detection: Insights From the DEPCDUO Study.Journal of medical virology · 2026Article
- Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.BMC gastroenterology · 2026Article
- Whole-Genome Bisulfite Sequencing Identifies Blood-Based DNA Methylation Biomarker for Hepatocellular Carcinoma.Molecular carcinogenesis · 2026Article
- Prediction of potential NS3-based T cell epitopes of hepatitis C virus by in-silico and in-vitro approach.Scientific reports · 2026Article
- Primary liver cancer in Georgia: Seven years' experience following the launch of the Hepatitis C Elimination Program, 2015-2022.PloS one · 2026Article
- Incidence and mortality trend of liver cancer in Iran from 1990 to 2021: an epidemiological investigation using the Global Burden of Disease study.Annals of medicine and surgery (2012) · 2025Article
- Metabolites involvement in the growth and spread of liver cancer.Liver research (Beijing, China) · 2025Review
- The role of AP2M1 in oncofetal characteristics: integrative in silico, in vitro, and in vivo analyses using zebrafish models.European journal of medical research · 2025Article
- Hepatocellular Carcinoma in Pacific Islanders vs. Whites.Hawai'i journal of health & social welfare · 2025Article
- A Quinoline Derivative HZ-6d Induces Antiviral Activity Against Hepatitis C Virus Via Apoptosis-Mediated Cytotoxicity.The Kobe journal of medical sciences · 2025Article
- Long-Term Benefits Following Hepatitis C Cure Through Facilitated Telemedicine; Experiences of People With Opioid use Disorder Five Years After Achieving a Sustained Virological Response.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- cfDNA Key genomic markers in HCV-Induced hepatocellular carcinoma in Egyptian patients.Journal, genetic engineering & biotechnology · 2025Article
- Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virology journal · 2025Review
- Hepatocellular Carcinoma: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025Review
- Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of liver-related death worldwide. Hepatitis C virus (HCV) infection is a major cause of advanced hepatic fibrosis and cirrhosis, with significantly increased risk for development of HCC. The morbidity and mortality of HCV-related HCC remains high, as rates of HCV cirrhosis continue to increase. The long-term goal of antiviral therapy for chronic HCV is to reduce complications from cirrhosis, including HCC. The advent of new direct-acting antivirals with high rates of virological clearance has revolutionized cure of HCV infection. While the development of HCC in HCV patients who achieve disease sustained virologic response is reduced, these patients remain at risk for HCC, particularly those patients with advanced fibrosis and cirrhosis. This review outlines the epidemiology of HCC in chronic HCV, various mechanisms, risk factors and pathophysiology that contribute to this disease process, screening recommendations, and the available data on the impact of new direct-acting antiviral treatment on the development on HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.